Respiratory bronchiolitis associated interstitial lung disease (RB-ILD): a case of an acute presentation

Mavridou, D.; Laws, D.
October 2004
Thorax;Oct2004, Vol. 59 Issue 10, p910
Academic Journal
Respiratory branchiolitis associated interstitial lung disease (RB-ILD) is a recently described clinicopathological entity that occurs almost exclusively in current heavy cigarette smokers. Few cases have been reported in the literature and no studies have been carried out on the effect of treatment, which currently consists of smoking cessation with or without corticosteroids. We report the first case of an acute presentation of histologically proven RB-ILD in a young cigarette smoker whose diagnosis and management proved to be difficult. Smoking cessation alone was found to be inadequate so management was combined with corticosteroid therapy


Related Articles

  • COPD Unwound. Shapiro, Steven D. // New England Journal of Medicine;5/12/2005, Vol. 352 Issue 19, p2016 

    Examines the genetic aspects of chronic obstructive pulmonary disease (COPD). Relationship between COPD and chromatin unwinding; Impact of cigarette smoke on genetic structure in patients with COPD; Comments on the use of corticosteroids in the treatment of COPD; Role of inflammatory cells...

  • Steroid Resistance in COPD? Overlap and Differential Anti-Inflammatory Effects in Smokers and Ex-Smokers. Hoonhorst, Susan J. M.; ten Hacken, Nick H. T.; Vonk, Judith M.; Timens, Wim; Hiemstra, Pieter S.; Lapperre, Thérèse S.; Sterk, Peter J.; Postma, Dirkje S. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Background: Inhaled corticosteroids (ICS) reduce exacerbation rates and improve health status but can increase the risk of pneumonia in COPD. The GLUCOLD study, investigating patients with mild-to-moderate COPD, has shown that long-term (2.5-year) ICS therapy induces anti-inflammatory effects....

  • NEWS ROUNDUP. Roberts, Meghan // Pulmonary Reviews;Mar2008, Vol. 13 Issue 3, p3 

    This section offers pulmonary health-related news briefs. According to a study, differences in the sleep EEG between smokers and nonsmokers may indicate nonrestorative sleep in smokers. Alvesco, an inhaled corticosteroid for the maintenance and treatment of asthma, has been approved by the U.S....

  • Changes in Airway Histone Deacetylase2 in Smokers and COPD with Inhaled Corticosteroids: A Randomized Controlled Trial Sohal, Sukhwinder Singh; Reid, David; Soltani, Amir; Weston, Steven; Muller, Hans Konrad; Wood-Baker, Richard; Walters, Eugene Haydn // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    The expression of HDAC2 is reported as reduced in chronic obstructive pulmonary disease (COPD). We assessed HDAC2 expression within the airways of smokers and subjects with COPD and effects of inhaled corticosteroids (ICS), using immuno-histology to contrast with previous molecular methodology....

  • Body Composition in Severe Refractory Asthma: Comparison with COPD Patients and Healthy Smokers. Minas, Markos; Papaioannou, Andriana I.; Tsaroucha, Agori; Daniil, Zoe; Hatzoglou, Chrissi; Sgantzos, Markos; Gourgoulianis, Konstantinos I.; Kostikas, Konstantinos // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    Background: Body composition is an important parameter for patients with chronic obstructive pulmonary disease (COPD) whereas the association between asthma and obesity is not fully understood. The impact of severe refractory asthma (SRA) on fat free mass (FFM) has not been investigated....

  • Base the decision to initiate oral corticosteroids in patients with pulmonary sarcoidosis on symptoms and disease severity.  // Drugs & Therapy Perspectives;Mar2008, Vol. 24 Issue 3, p12 

    Pulmonary sarcoidosis is the most frequently occurring parenchymal disease. Initiation of therapy is based on symptoms and disease severity, with oral corticosteroids being the cornerstone of therapy. Although treatment with oral corticosteroids is associated with short- to medium-term...

  • Five days of corticosteroid for exacerbations of COPD.  // BMJ: British Medical Journal;6/1/2013, Vol. 346 Issue 7910, p11 

    The article reports that five days of oral prednisolone are sufficient for most people with an acute exacerbation of chronic obstructive pulmonary disease (COPD) and states that it works well against corticosteroid and limit exposure and side effects of drugs.

  • The impact of budesonide/formoterol in health status and morning symptoms. Calverley, Peter M.A. // Hot Topics in Respiratory Medicine;2011, Vol. 6 Issue 18, p17 

    There is now a sound rationale for combining inhaled corticosteroids (ICSs) and long-acting beta2-agonists in severe chronic obstructive pulmonary disease (COPD), and this is reflected in the recommendations in current treatment guidelines. Health status, frequency of exacerbations, use of oral...

  • NICE guidance for COPD.  // Nursing & Residential Care;Feb2014, Vol. 16 Issue 2, p69 

    No abstract available.


Read the Article


Sign out of this library

Other Topics